Authors
Latest:
Validation of Large-Scale Chromatographic Processes, Part 2: Results from the Case Study of Neuleze Capture on Macroprep High-Sby Timothy N. Breece, Ellen Gilkerson, and Charles Schmelzer, Genentech, Inc.
Latest:
Development of an In Situ Spectroscopic Method for Cleaning Validation using Mid-IR Fiber-Opticsby Narinder K. Mehta, Javier Goenaga-Polo, Samuel P. Hernandez-Rivera, David Hernandez, Peter J. Melling, and Mary A. Thomson, Remspec Corporation A fiber-optic, mid-IR spectroscopy probe combined with a grazing-angle reflectance sampling head can be used as a solvent-free in situ method for validating cleanliness with substantial improvement in accuracy.
Latest:
Development of an In Situ Spectroscopic Method for Cleaning Validation using Mid-IR Fiber-Opticsby Narinder K. Mehta, Javier Goenaga-Polo, Samuel P. Hernandez-Rivera, David Hernandez, Peter J. Melling, and Mary A. Thomson, Remspec Corporation A fiber-optic, mid-IR spectroscopy probe combined with a grazing-angle reflectance sampling head can be used as a solvent-free in situ method for validating cleanliness with substantial improvement in accuracy.
Latest:
Development of an In Situ Spectroscopic Method for Cleaning Validation using Mid-IR Fiber-Opticsby Narinder K. Mehta, Javier Goenaga-Polo, Samuel P. Hernandez-Rivera, David Hernandez, Peter J. Melling, and Mary A. Thomson, Remspec Corporation A fiber-optic, mid-IR spectroscopy probe combined with a grazing-angle reflectance sampling head can be used as a solvent-free in situ method for validating cleanliness with substantial improvement in accuracy.
Latest:
Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques ? and the Magnitude of Freeze-Concentrationby Serena Donnelly Webb, David F. Sesin, Aimee C. Kincaid, Jonathan N. Webb, and Timothy G. Hughes, Integrated Biosystems, Inc. Large-scale freezing and thawing is commonly used in biopharmaceutical manufacturing but is not well understood. Freeze-thaw variations can exist within or between batches, and nonuniform processes raise serious validation concerns.
Latest:
Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques ? and the Magnitude of Freeze-Concentrationby Serena Donnelly Webb, David F. Sesin, Aimee C. Kincaid, Jonathan N. Webb, and Timothy G. Hughes, Integrated Biosystems, Inc. Large-scale freezing and thawing is commonly used in biopharmaceutical manufacturing but is not well understood. Freeze-thaw variations can exist within or between batches, and nonuniform processes raise serious validation concerns.
Latest:
Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques ? and the Magnitude of Freeze-Concentrationby Serena Donnelly Webb, David F. Sesin, Aimee C. Kincaid, Jonathan N. Webb, and Timothy G. Hughes, Integrated Biosystems, Inc. Large-scale freezing and thawing is commonly used in biopharmaceutical manufacturing but is not well understood. Freeze-thaw variations can exist within or between batches, and nonuniform processes raise serious validation concerns.
Latest:
Analytical Advances: Strategies in Clarifying Mammalian Culturesby Charles Lambalot, Millipore Corporation
Latest:
Outsourcing Outlook: E-Procurement ? Successfully Using and Managing Reverse Auctionsby Jim Miller, and Edward P. Miller, PharmSource Informaton Services, Inc. Today, reverse auctions are perceived more realistically than in years past, but they still offer many benefits for both buyer and seller.
Latest:
Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques ? and the Magnitude of Freeze-Concentrationby Serena Donnelly Webb, David F. Sesin, Aimee C. Kincaid, Jonathan N. Webb, and Timothy G. Hughes, Integrated Biosystems, Inc. Large-scale freezing and thawing is commonly used in biopharmaceutical manufacturing but is not well understood. Freeze-thaw variations can exist within or between batches, and nonuniform processes raise serious validation concerns.
Latest:
Analytical Advances: Using Image Informatics - Focusing Proteomicsby Suzanne Mattingly, Scimagix, Inc.
Latest:
Freezing Bulk-Scale Biopharmaceuticals Using Common Techniques ? and the Magnitude of Freeze-Concentrationby Serena Donnelly Webb, David F. Sesin, Aimee C. Kincaid, Jonathan N. Webb, and Timothy G. Hughes, Integrated Biosystems, Inc. Large-scale freezing and thawing is commonly used in biopharmaceutical manufacturing but is not well understood. Freeze-thaw variations can exist within or between batches, and nonuniform processes raise serious validation concerns.
Latest:
Finding Funding in Biotechnology: Keeping the Companies Aliveby Mark D. Dibner, BioAbility, LLC, and Michael Howell Biotechnology appears to be "the place to be" for venture capitalists, capturing the largest percentage increase in investment for 2001. The value of biotech companies has risen sharply, and many economists are predicing an end to the IPO drought.
Latest:
Guest Editorial: Supreme Court Rules on FestoSome good news, some bad news for biotechnology patent holders
Latest:
Unlocking the Value of R&D: Managing the Risksby Duncan Pass, and Martyn Postle, Cambridge Pharma Consultancy How does big pharma look at your biotech company as a potential partner? This often depends on how it looks at its own research and development investments ? and how it presents them to shareholders. This insider's look at biotech-pharma collaboration shows you the other side of the equation.
Latest:
Negotiating and Structuring Strategic Alliancesby David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
Latest:
Negotiating and Structuring Strategic Alliancesby David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
Latest:
Negotiating and Structuring Strategic Alliancesby David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
Latest:
Finding Funding in Biotechnology: Keeping the Companies Aliveby Mark D. Dibner, BioAbility, LLC, and Michael Howell Biotechnology appears to be "the place to be" for venture capitalists, capturing the largest percentage increase in investment for 2001. The value of biotech companies has risen sharply, and many economists are predicing an end to the IPO drought.
Latest:
Unlocking the Value of R&D: Managing the Risksby Duncan Pass, and Martyn Postle, Cambridge Pharma Consultancy How does big pharma look at your biotech company as a potential partner? This often depends on how it looks at its own research and development investments ? and how it presents them to shareholders. This insider's look at biotech-pharma collaboration shows you the other side of the equation.
Latest:
Negotiating and Structuring Strategic Alliancesby David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
Latest:
Criminal Penalties for Theft of Biological Materialby Liz Howard, Orrick, Herrington & Sutcliff, LLP Trade secret theft and economic espionage laws apply to biopharmaceutical researchers. Learn what your company needs to do to retain protection under the Economic Espionage Act and what employees need to know to pretect themselves from criminal charges.
Latest:
Outsourcing Outlook: E-Procurement - Reverse Auctions and the Seller's Perspective.by Jim Miller, PharmSource Information Services, Inc. and Edward P. Moser
Latest:
Guest Editorial: Enabling Collaboration in the Pharmaceutical Industryby Francois Gossieaux, eRoom Technology, Inc.
Latest:
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesby Linda Magee, Bionow The United Kingdom has the second largest biotechnology industry in the world, a leading position in Europe, an excellent science base, proven capability in the development of drug candidates, and a record of several firsts in technology development.
Latest:
Optimizing Recombinant Microbial Fermentation Processes: An Integrated Approachby Karl Bayer, Monika Cserjan-Puschmann, Reingard Grabherr, Gerald Striedner, and Franz Clementschitsch, Institute of Applied Microbiology, Vienna, Austria A new strategy for controlling recombinant gene expression improves efficiency, maximizes host vector exploitation, reduces costs, improves product consistency, and accelerates product development. Continuous feeds of limited amounts of inducer proportional to biomass growth grant optimal control over the ratio between gene expression and host cell metabolism, providing stable, prolonged recombinant protein production.
Latest:
Targeted Biomarketing: Helping Biotech Businesses Growby Eric DeRitis, Real PR Network Communicating presents an image of openness, engendering trust; when you don't communicate, people soon think the worst. Biopharmaceutical companies frequently ignore corporate marketing until too late in the game: Public relations should start at inception to help companies start out correctly.
Latest:
Validation of Large-Scale Chromatographic Processes, Part 2: Results from the Case Study of Neuleze Capture on Macroprep High-Sby Timothy N. Breece, Ellen Gilkerson, and Charles Schmelzer, Genentech, Inc.
